Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and safety study of EB-1020 XR in healthy Japanese males
jRCT2071220029Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (7 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety endpoints and Pharmacokinetic endpoints. Started Jul 2022; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2071220029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220029.